Combining CT-based radiomics and deep learning features with clinical data enhances prediction of hepatocellular carcinoma risk in cirrhosis patients.
Key Details
- 1Study used a multicenter, prospective cohort of 2,411 cirrhosis patients in China (2018–2023).
- 2All patients underwent 3-phase contrast-enhanced abdominal CT at baseline.
- 3AI model extracted radiomics (PyRadiomics) and deep learning (ResNet-18) features from liver and spleen on CT.
- 4The integrated aMAP-CT model significantly outperformed standard clinical models (AUC 0.809–0.869).
- 5Model stratified patients into high- (26.3% incidence) and low-risk (1.7%) groups over three years.
- 6Stepwise application identified 7% of patients at very high risk for HCC (27.2% three-year incidence).
Why It Matters
This study demonstrates how AI-driven analysis of imaging data can meaningfully improve personalized risk stratification in a major oncologic domain, supporting earlier HCC detection and potentially better clinical outcomes for high-risk cirrhosis patients.
Source
EurekAlert
Related News
•EurekAlert
AI Accelerates Radiopharmaceuticals, Boosts Personalized Dosimetry in Cancer
Machine learning is driving advancements in radiopharmaceutical drug discovery and optimizing patient-specific dosimetry for precision cancer therapy.
•EurekAlert
Physicians Overly Trust Erroneous AI, Ignore Contradictory Evidence
Physicians tend to trust incorrect AI advice, even when evidence contradicts it, suggesting risks in clinical decision-making with AI tools.
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.